Zevra Therapeutics, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $34M | ↑+183.4% | $12M | — | — |
| 2025-09-30 | $26M | ↑+605.4% | $-544K | ↑+98.4% | 15.9% |
| 2025-06-30 | $26M | ↑+481.7% | $75M | ↑+474.9% | -274.5% |
| 2025-03-31 | $20M | ↑+495.6% | $-3M | ↑+81.4% | -26.3% |
| 2024-12-31 | $12M | ↓-6.8% | — | — | — |
| 2024-09-30 | $4M | ↑+27.6% | $-33M | ↓-220.5% | -739.0% |
| 2024-06-30 | $4M | ↓-47.5% | $-20M | ↓-674.4% | -534.8% |
| 2024-03-31 | $3M | ↑+7.8% | $-17M | ↓-25.8% | -598.1% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$34M
↑+183.4% +$22M YoY
Net Income
$7M
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
ZVRA Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyZVRA Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics